LatticeFlow AI Introduces Suite 2.0 to Enhance Performance, Reliability, and Compliance in AI Systems
26.11.2024 11:10:00 CET | Business Wire | Press Release
LatticeFlow AI, a leader in enabling organizations to build trustworthy AI systems, today introduced its Suite 2.0 to elevate performance, reliability, and compliance of AI systems.
As the next generation of AI systems must be built from the ground up to be trustworthy and compliant, LatticeFlow AI Suite 2.0 bridges critical gaps between machine learning operations, technical validation, and regulatory demands, empowering organizations to deploy AI systems that drive business value, and excel in safety, trustworthiness, and regulatory compliance.
The Last Mile of AI
While new tools and open-source resources have made AI development easier, few AI models successfully transition to production and consistently deliver business value. Emerging AI regulations and internal risks—such as model blind spots and safety concerns—add complexity, requiring AI models to be resilient and compliant before deployment.
To address these challenges, LatticeFlow AI presented the concept of The Last Mile of AI, a framework for the critical, final steps to ensure successful AI deployments. The Last Mile of AI encompasses five essential challenges: validate data, accelerate model performance, automate internal AI controls, achieve regulatory compliance, and monitor ongoing risks and performance. With its Suite 2.0, LatticeFlow AI guides organizations through this “last mile,” enabling them to deliver AI systems that are not only technically performant but also robust, safe, and compliant.
“We are at a pivotal time in AI, where safety, security, and compliance are no longer optional. LatticeFlow AI is leading this evolution by automating key AI quality and risk controls, empowering teams to confidently navigate the last mile of AI, and ensuring their AI applications are high-performing, trustworthy, and safe for society,” said Dr. Petar Tsankov, CEO and Co-Founder of LatticeFlow AI.
Automated AI Health Checks: Proactive AI Control and Model Validation
As a core feature of the Suite 2.0, LatticeFlow AI introduces Health Checks, a groundbreaking capability that enables organizations to establish and automate internal controls for AI model performance and data quality. Health Checks allow teams to standardize quality evaluations across their AI models tailored to each company’s needs. The suite contains a library of pre-defined checks that can be customized to the use cases at hand and offers the ability to create custom checks relevant for a company’s domain. Health Checks operate on both data and model levels.
Data Health Checks provide expert-level analysis at the sample and annotation level, accelerating data preparation and preventing costly model errors. Pre-defined checks flag duplicate images, leaked samples, or mislabeled items. Custom checks allow monitoring use case-specific scenarios such as “images should not be rotated” with every dataset update.
Model Health Checks not only run basic sanity checks but also proactively detect risks such as model underperformance for specific metadata, both for default categories like image brightness and for custom concepts such as “images with people wearing glasses.” The suite offers multiple ways to detect and monitor potential blind spots, ensuring standardized diagnostics for different model versions and reinforcing compliance with both internal and regulatory standards.
By automating these processes, Health Checks allows AI teams to work more efficiently, enabling smaller teams to achieve expert-level insights without time-intensive manual processes or extensive data exploration. Most importantly, Health Checks enables executives to have full visibility into the quality and performance of their AI applications.
Jumio, a leading provider of AI-driven identity verification and compliance solutions, has partnered with LatticeFlow AI to build on the power of automated Health Checks. “Ensuring that our AI models are both safe and reliable is critical to providing the highest level of protection for our customers,” said Alix Melchy, Jumio VP of AI. “By partnering with LatticeFlow AI, we’re taking a proactive approach to identifying potential risks and enhancing the security of our AI models. This partnership is not just about improving performance—it’s about staying ahead of industry regulations and ensuring compliance with emerging AI standards.”
About LatticeFlow AI
LatticeFlow AI enables organizations to build performant, trustworthy, and compliant AI applications. As a pioneer in AI validation, LatticeFlow AI has developed COMPL-AI—the industry’s first comprehensive EU AI Act mapping in partnership with ETH Zurich and INSAIT, helping AI teams align with regulatory standards.
With Swiss government funding, LatticeFlow AI is advancing AI Assessments, a platform bridging AI governance and technical validation to meet evolving compliance and risk management needs.
Globally recognized for its impact, LatticeFlow AI has received the US Army Global Award and been named to CB Insights’ AI100 list of the world’s most innovative AI companies. As AI enters a critical phase, LatticeFlow AI empowers companies to deploy AI solutions that are resilient, compliant, and high performing.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126720784/en/
Contacts
Media Enquiries:
Gloria Fernandez, Marketing Director
media@latticeflow.ai
LatticeFlow AI
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom